Feb. 25 at 9:16 PM
$RCUS Q4 '25 Earnings Results & Recap
• Reported GAAP EPS of -
$0.89 up 13.59% YoY
• Reported revenue of
$33M down -8.33% YoY
• Arcus Biosciences expects GAAP revenue for the full year 2026 to be between
$45M, with R&D expenses projected to decrease meaningfully. Arcus also anticipates its cash runway will extend until at least the second half of 2028.
